Merck (MRK) released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA is reviewing the application for approval. The data showed that ...

Merck & Co. is handing over $200 million to China ... Eli Lilly has its own Lp(a) inhibitor in the clinic in the form of muvalaplin, which was shown to successfully reduce levels of the ...

Lusaka [Zambia] / Mumbai (Maharashtra) [India], April 7: Merck Foundation, the philanthropic arm of Merck KGaA Germany marks 'World Health Day' 2025 in partnership with Africa's First Ladies who ...

Merck has recently achieved a significant milestone with the European Commission's approval of its pneumococcal vaccine CAPVAXIVE®, boosting its portfolio in the vaccines market. Despite this ...

Merck's stock trades at a low valuation as investors ... The big question is, even if successful, whether many patients will opt for the new form of treatment, which may be more convenient ...

Patient centricity is a priority for Merck and its Executive Vice President and Head of EMEA Region for Merck Biopharma Global Commercial Operations, Chris Round, outlines what practical steps the ...

40% of Merck & Co., Inc.'s revenues are driven by cancer med Keytruda, which faces patent expiry by 2028, posing a significant risk to future earnings and share price value. The company is ...

Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Merck To Contact Him Directly To Discuss Their Options ...

Merck (MRK) has signed a licensing agreement for a heart disease drug developed by a Chinese company in a deal worth up to $2 billion, the latest in a series of cross-border deals between Western ...

The patient support program Cycle Vita will be available for people with MS taking Bafiertam (monomethyl fumarate) starting in April.

For some years industry observers have been asking what Merck & Co can do to reduce its ... fraction (HFrEF), which could triple the eligible patient population for the drug.